Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, B-Cell

Explore clinical trials studying Lymphoma, B-Cell. Study availability and eligibility vary by location and protocol.

503 public trials 139 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, B-Cell trial results

Completed

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

NCT00312845

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • East Alabama Medical Center Opelika, Alabama, United States
  • Central Hematology Oncology Medical Group, Inc Alhambra, California, United States
  • Comprehensive Blood and Cancer Center Bakersfield, California, United States
  • Providence Saint Joseph Medical Center Burbank, California, United States
View all 206 locations
View Trial Details
Completed

Treatment of Mature B-cell Lymphoma/Leukaemia

NCT00162656

Conditions
B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Morgan Stanley Childrens Hospital of New York Presbyterian New York, United States
  • Institut Gustave Roussy Villejuif, France
  • Sheffield Children's Hospital Sheffield, United Kingdom
View Trial Details
Completed

A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma

NCT00211276

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Tower Cancer Research Foundation Beverly Hills, California, United States
  • Pacific Coast Hematology/Oncology Fountain Valley, California, United States
  • University of California, Los Angeles Los Angeles, California, United States
  • Emory University Atlanta, Georgia, United States
View Trial Details
Completed

Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen

NCT01478269

Conditions
B-Cell Lymphomas, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
Locations
  • Hemocentro-Unicamp Campinas, Brazil
  • Centro Medico Santa Isabel, Brazil
  • Centro Paulista de Oncologia São Paulo, Brazil
  • Santa Casa Medical School São Paulo, Brazil
View all 39 locations
View Trial Details
Completed

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

NCT00051597

Conditions
DNA Virus Infections, Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, +22 more
Locations
  • University of Alabama, Birmingham Birmingham, Alabama, United States
  • USC Norris Cancer Center Los Angeles, California, United States
  • University of Miami Miami, Florida, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details

Related conditions